Doxorubicin for Metastatic Breast Cancer: Time for a Change?

Cancer Investigation

Volumn 21, Issue 6, 2003, Pages 967-968

  Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAEKYX; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOKINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FOLIC ACID ANTAGONIST; GEMCITABINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCA ALKALOID;

ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EDITORIAL; HUMAN; KAPOSI SARCOMA; MAINTENANCE THERAPY; METASTASIS; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SKIN TOXICITY; SURVIVAL RATE;

EID: 0346727407     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120025100     Document Type: Editorial

References (9)

1. Slamon, D.J.; Leyland-Jones, B.; Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. New Eng. J. Med. 2001, 344, 783-792.
2. O'Shaughnessy, J.; Miles, D.; Vukelja, S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002, 20(12), 2812-2823.
3. Chao, T.-C.; Wang, J.-C.; Yen, C.-C., et al. A dose-escalating pilot study of sterically stabilized pegylated liposome doxorubicin (Lipo-Dox®) in patients with metastatic breast cancer. Cancer Invest, (this issue).
4. Coates, A.; Gebski, V.; Stat, M., et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 1987, 317, 1490-1497.
5. Wigler, N.; Inbar, M.; O'Brien, R., et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal dosxorubicin (Caelyx, Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 45a, (abstract 177).
6. Wasserheit, C.; Downey, A.; Sorich, J., et al. A phase I study of taxotere and doxil in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 1999, 18, 642.
7. Sparano, J.; Malik, U.; Rajdev, L., et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J. Clin. Oncol. 2001, 19, 3117-3225.
8. 2. Ann. Oncol. 2000, 11, 1029-1033.
9. Hamilton, A.; Biganzoli, L.; Coleman, R., et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Ann. Oncol. 2002, 13, 910-918.